Powered by

Imcyse completes enrolment in Phase Ib trial of Imotopes

Nov 06, 2018 - Marketline Newswire

Imcyse has completed patient enrolment in its first-in-human Phase Ib clinical trial to examine the safety, immunological responses and clinical impact of Imotopes for the treatment of type 1 diabetes.

Type 1 diabetes is currently estimated to affect more than 40 million people worldwide and the disease is growing in high-income countries at an annual rate of nearly 3%.The double-blind, placebo-controlled, dose-escalation trial has enrolled 41 patients with insulin-dependent type 1 diabete...